Search - tctmd.com

Displaying 101 - 120 of 879

Sort: Relevancy | Date

News Conference News TCT 2022

FAVOR III China: Early Gains of QFR in PCI Persist to 2 Years

L.A. McKeown

September 20, 2022

News Conference News TCT 2022

SCAAR Registry Delves Into Left Main Revascularization Outcomes

Michael O'Riordan

September 19, 2022

Presentation TCT 2022

Two-Year Outcomes of the Randomized Second-Generation Drug-Eluting Stents in Diabetes (SUGAR) Trial

Presenter: Pablo Salinas

September 19, 2022

Presentation TCT 2022

TCT 167: Percutaneous Coronary Intervention with Ultrathin-Strut Biodegradable versus Thin-Strut Durable Polymer Drug-Eluting Stents of Lesions Requiring Multiple Stents: A Lesion-Level Subgroup Analysis of the Combined BIOSCIENCE and BIOSTEMI Randomized…

Presenter: Jonas Haener

September 19, 2022

Presentation TCT 2022

EXpansion of Stents After Intravascular lithoTripsy vs Conventional Predilatation in CALCified Coronary Arteries

Presenter: Maarten Vink

September 19, 2022

Presentation TCT 2022

Everolimus-Eluting Stents or Bypass Surgery for Mutivessel Coronary Artery Disease: 10-Year Outcomes of Multicenter Randomized Controlled BEST Trial

Presenter: Jung-Min Ahn

September 19, 2022

Presentation TCT 2022

TCT 51: Assessment of Durable Polymer and Biodegradable Polymer Drug-Eluting Stents After Percutaneous Coronary Intervention in Patients With ST-Elevation Myocardial Infarction

Presenter: Gustavo Araújo

September 17, 2022

Presentation TCT 2022

Percutaneous CABG - How Many Stents Are Too Many? Implications for Multivessel Stenting

Presenter: Andrew Goldsweig

September 16, 2022

News Conference News TCT 2021

Debating ISCHEMIA: Do the Results Apply to CABG, Too?

Michael O'Riordan

November 10, 2021

Presentation TCT 2021

TIDES-ACS: Three-Year Outcomes From a Randomized Trial of Titanium Nitride Oxide-Coated Versus Everolimus-eluting Stents in Patients With Acute Coronary Syndromes

Presenter: Pasi Karjalainen

November 06, 2021

Presentation TCT 2021

BIODEGRADE: Three-Year Outcomes From a Randomized Trial of Biolimus-eluting Versus Zotarolimus-eluting Stents in Patients With Coronary Artery Disease

Presenter: IN-HO CHAE

November 06, 2021

Presentation TCT 2021

BIO-RESORT: Five-Year Outcomes from a Randomized Trial of Three Drug-Eluting Stents in Patients With Coronary Artery Disease

Presenter: Eline Ploumen

November 06, 2021

News Conference News TCT 2021

DCBs in Coronaries? Some Good News, but More Work Needed

L.A. McKeown

November 06, 2021

News Conference News TCT 2021

More DAPT Duration Data, More Calls to Tailor to Individual Patients

Shelley Wood

November 05, 2021

News Conference News TCT 2021

Disrupt CAD III Shows Sustained Benefit for Lithotripsy at 1 Year

L.A. McKeown

November 05, 2021

News Conference News TCT 2021

More Complications With Plug Closure After TAVI: CHOICE-CLOSURE

Michael O'Riordan

November 05, 2021

News Conference News TCT 2021

TAVI Edges Out Surgery in 2-Year Costs for Low-risk Patients: PARTNER 3

Yael L. Maxwell

November 05, 2021

Presentation TCT 2021

Case 3: Planned Two Stents and Why I Chose This Two-Stent Technique

Presenter: Sahil Khera

November 04, 2021

Presentation TCT 2021

Case 2: Provisional Ending With Two Stents

Presenter: Katherine Kunkel

November 04, 2021

News Conference News TCT 2021

iFR Matches FFR Through 5 Years: iFR-SWEDEHEART

Caitlin E. Cox

November 04, 2021

Advertisement

FAVOR III China: Early Gains of QFR in PCI Persist to 2 Years

SCAAR Registry Delves Into Left Main Revascularization Outcomes

Two-Year Outcomes of the Randomized Second-Generation Drug-Eluting Stents in Diabetes (SUGAR) Trial

TCT 167: Percutaneous Coronary Intervention with Ultrathin-Strut Biodegradable versus Thin-Strut Durable Polymer Drug-Eluting Stents of Lesions Requiring Multiple Stents: A Lesion-Level Subgroup Analysis of the Combined BIOSCIENCE and BIOSTEMI Randomized…

EXpansion of Stents After Intravascular lithoTripsy vs Conventional Predilatation in CALCified Coronary Arteries

Everolimus-Eluting Stents or Bypass Surgery for Mutivessel Coronary Artery Disease: 10-Year Outcomes of Multicenter Randomized Controlled BEST Trial

TCT 51: Assessment of Durable Polymer and Biodegradable Polymer Drug-Eluting Stents After Percutaneous Coronary Intervention in Patients With ST-Elevation Myocardial Infarction

Percutaneous CABG - How Many Stents Are Too Many? Implications for Multivessel Stenting

Debating ISCHEMIA: Do the Results Apply to CABG, Too?

TIDES-ACS: Three-Year Outcomes From a Randomized Trial of Titanium Nitride Oxide-Coated Versus Everolimus-eluting Stents in Patients With Acute Coronary Syndromes

BIODEGRADE: Three-Year Outcomes From a Randomized Trial of Biolimus-eluting Versus Zotarolimus-eluting Stents in Patients With Coronary Artery Disease

BIO-RESORT: Five-Year Outcomes from a Randomized Trial of Three Drug-Eluting Stents in Patients With Coronary Artery Disease

DCBs in Coronaries? Some Good News, but More Work Needed

More DAPT Duration Data, More Calls to Tailor to Individual Patients

Disrupt CAD III Shows Sustained Benefit for Lithotripsy at 1 Year

More Complications With Plug Closure After TAVI: CHOICE-CLOSURE

TAVI Edges Out Surgery in 2-Year Costs for Low-risk Patients: PARTNER 3

Case 3: Planned Two Stents and Why I Chose This Two-Stent Technique

Case 2: Provisional Ending With Two Stents

iFR Matches FFR Through 5 Years: iFR-SWEDEHEART

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content